Dr. James Helliwell reports

EUPRAXIA PHARMACEUTICALS APPOINTS DR. JEYMI TAMBIAH AS CHIEF MEDICAL OFFICER

Eupraxia Pharmaceuticals Inc. has appointed Dr. Jeymi Tambiah as chief medical officer (CMO). Dr. Mark Kowalski, Eupraxia's current CMO, has retired.

Dr. Tambiah (MB ChB, FRCS, MS, FAPCR, FFPM), is a board-certified cardiothoracic surgeon physician scientist who practiced at Guy's and St Thomas' hospitals prior to entering the biopharmaceutical industry in 2008. Dr. Tambiah brings over 18 years of experience in clinical development, medical and regulatory strategy, and product commercialization across pharmaceutical and biotechnology organizations.

"I am excited to welcome Dr. Tambiah at such a pivotal development stage for Eupraxia as we advance EP-104GI in eosinophilic esophagitis. His extensive development and leadership experience will help drive the late-stage development and expansion of our gastroenterology pipeline. Jeymi's deep clinical, regulatory and operational experience add additional core strength to Eupraxia's executive leadership," said Dr. James A. Helliwell, chief executive officer of Eupraxia. "I also want to thank Dr. Kowalski for his important contributions in helping bring the company to this clinical stage. On behalf of all of us, I want to thank him for his leadership and wish him the very best in his retirement and his support as a senior consultant through the transition."

Dr. Tambiah has a strong record of leading cross functional teams and advancing immunology programs, including novel therapeutics, through key late-stage clinical and regulatory milestones.

"Eupraxia is at an exciting development stage with EP-104GI in EoE with several key data catalysts in the near term and the opportunity to expand into other important areas in gastroenterology. With so much opportunity to drive programs in areas of high unmet need into late-stage clinical development, combined with the additional possibilities of the Diffusphere platform, I am thrilled to join Eupraxia and work with the team to bring therapies like these to patients," said Dr Tambiah.

Dr. Tambiah earned his MBChB from the University of Manchester, his master of surgery from Imperial College London, and trained as a cardiothoracic surgery specialist at the London Chest Hospital, and at Guy's and St Thomas' hospitals in the United Kingdom. He also completed his doctorate in vascular immunology at Imperial College and is a fellow of the Royal College of Physicians and Surgeons.

About Eupraxia Pharmaceuticals Inc.

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere, a proprietary, polymer-based microsphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyperlocalized fashion, targeting only the tissues that physicians are wanting to treat. The company believes the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the Diffusphere technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's Diffusphere technology platform has the potential to augment and transform existing FDA-approved (U.S. Food and Drug Administration) drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.

Eupraxia's EP-104GI is currently in a phase 1b/2 trial, the Resolve trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also completed a phase 2b clinical trial (Springboard) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary end point and three of the four secondary end points. In addition, Eupraxia is developing a pipeline of later- and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs.

We seek Safe Harbor.